Clovis Oncology (CLVS) Misses Q4 EPS by 25c

February 23, 2021 8:02 AM EST

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Clovis Oncology (NASDAQ: CLVS) reported Q4 EPS of ($1.02), $0.25 worse than the analyst estimate of ($0.77). Revenue for the quarter came in at $43.3 million versus the consensus estimate of $43.22 million.

For earnings history and earnings-related data on Clovis Oncology (CLVS) click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories


Related Entities